By Nono Hu, Senior Manager, Branding & Messaging, LSN
This Monday, RESI came to TMCx, the Texas Medical Center’s 100,000-square-foot accelerator space. RESI @ TMCx featured approximately 150 investors, 250 biotech, medtech and healthcare IT entrepreneurs, and 60 service providers.
In the exhibit hall, 34 of the most innovative early stage life science companies at the event were chosen to participate in a virtual investment contest – The RESI Innovation Challenge, showcasing cutting-edge life science technologies in poster displays and competing to raise the most RESI Cash. Without further ado here are the top 3 contestants!
First Prize Winner: Redox
Redox is the modern API for healthcare integration. Redox helps developers integrate with EHRs and health systems manage their connections to the cloud. The Redox Engine de-risks software implementations by enabling turnkey EHR integration with any application you choose to work with.
As a first prize winner, Redox will receive complimentary subscription to the LSN Investor Platform.
Second Prize Winner: NeuroFx
NeuroFx has developed an innovative, cell-free therapeutic factor concentrate derived from adult adipose (fat) stem cells that has demonstrated great potential based on animal testing to not only reduce brain injury caused by stroke, but in addition promote regeneration and repair of brain tissues. The founders of NeuroFx, together with its management team, have extensive experience in stem cell research and development and/or the necessary backgrounds in product commercialization to bring this therapeutic asset to market. NeuroFx will pursue development of additional indications for its products by partnering with pharmaceutical, regenerative medicine or medical device companies. The funding NeuroFx is seeking is to support its IND application and complete a Phase 1 trial.
As a second prize winner, NeuroFx will receive two complimentary RESI tickets.
Third Prize Winner: TeVido BioDevices
TeVido BioDevices uses innovative 3D bio-printing of a woman’s own living cells – to develop custom grafts for breast cancer reconstruction. The first product is targeted to improve nipple reconstruction, where current procedures often flatten and fade over time. TeVido has a platform technology that addresses a significant unmet need in the broad field of reconstructive and aesthetic surgery, a market estimated to be $6B globally.
As a third prize winner, TeVido will receive one complimentary RESI ticket.